Preclinical and clinical studies in other epithelial cancers, such as colorectal (Dutta et al., 2024; Tapia-Galisteo et al., 2022) and ovarian carcinomas (Fu et al., 2021; Li et al., 2023b; Richter et al., 2010), have explored EpCAM-directed approaches, including bispecific T cell engagers (catumaxomab targeting EpCAM x CD3) and chimeric antigen receptor (CAR) T cell therapies. This evidence concerns the gene EPCAM and ovarian carcinoma.